GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhoenixBio Co Ltd (TSE:6190) » Definitions » EV-to-EBITDA

PhoenixBio Co (TSE:6190) EV-to-EBITDA : 12.86 (As of Jun. 02, 2025)


View and export this data going back to 2016. Start your Free Trial

What is PhoenixBio Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PhoenixBio Co's enterprise value is 円807 Mil. PhoenixBio Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was 円63 Mil. Therefore, PhoenixBio Co's EV-to-EBITDA for today is 12.86.

The historical rank and industry rank for PhoenixBio Co's EV-to-EBITDA or its related term are showing as below:

TSE:6190' s EV-to-EBITDA Range Over the Past 10 Years
Min: -414.89   Med: -3.73   Max: 144.52
Current: 12.86

During the past 10 years, the highest EV-to-EBITDA of PhoenixBio Co was 144.52. The lowest was -414.89. And the median was -3.73.

TSE:6190's EV-to-EBITDA is ranked worse than
58.62% of 493 companies
in the Biotechnology industry
Industry Median: 8.65 vs TSE:6190: 12.86

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-02), PhoenixBio Co's stock price is 円388.00. PhoenixBio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was 円3.288. Therefore, PhoenixBio Co's PE Ratio (TTM) for today is 118.00.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


PhoenixBio Co EV-to-EBITDA Historical Data

The historical data trend for PhoenixBio Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhoenixBio Co EV-to-EBITDA Chart

PhoenixBio Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.58 -10.38 -4.73 3.37 14.56

PhoenixBio Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.60 7.21 8.58 14.56 -742.15

Competitive Comparison of PhoenixBio Co's EV-to-EBITDA

For the Biotechnology subindustry, PhoenixBio Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhoenixBio Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhoenixBio Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PhoenixBio Co's EV-to-EBITDA falls into.


;
;

PhoenixBio Co EV-to-EBITDA Calculation

PhoenixBio Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=806.597/62.712
=12.86

PhoenixBio Co's current Enterprise Value is 円807 Mil.
PhoenixBio Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhoenixBio Co  (TSE:6190) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

PhoenixBio Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=388.00/3.288
=118.00

PhoenixBio Co's share price for today is 円388.00.
PhoenixBio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3.288.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


PhoenixBio Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PhoenixBio Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PhoenixBio Co Business Description

Traded in Other Exchanges
N/A
Address
3-4-1, Kagamiyama, Hiroshima Prefecture, Higashi-Hiroshima, JPN, 739-0046
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics related test, safety test, hepatitis virus (HBV / HCV) related drug efficacy test.

PhoenixBio Co Headlines

No Headlines